Professional Documents
Culture Documents
Yot Teerawattananon
Country and organizational profile
Population: 67 millions
Health expenditure: 5% of
Health expenditure: 5% of
GDP (Public 70%)
Establishment of the
Establishment of the
Universal Healthcare Scheme
in 2002 to compliment the
Social Security Scheme and
Civil Servant Medical Benefit
Scheme
HITAP
HITAP (2007): a research arm of the Bureau of Health
(2007): a research arm of the Bureau of Health
Policy and Strategy, Ministry of Public Health
Appraising a wide range of health interventions and
pp g g
technologies including health promotion and public policy 2
The National List of Essential Medicines (NLEM)
Referred by three schemes as the pharmaceutical reimbursement
list
The current version, contains 800
800+ drugs, was launch in 2010
Pharmacoeconomic data was considered for the first time in the
selection of the MLEM in 2008 revision
Coverage
Drugs under consideration ICER (Baht/QALY) Year
decisions
pegylate interferon alpha 2b plus ribavirin for treatment of chronic
cost-saving Yes 2011
hepatitis C sybtype 145&6
pegylate interferon alpha 2a plus ribavirin for treatment of chronic
cost-saving Yes 2011
hepatitis C sybtype 145&6
lamivudine or tenofovir for treatment of chronic hepatitis B cost-saving Yes 2011
2 weeks
The Subcommittee for Development of NLEM
- Setting criteria for drug selection and prioritizing those drugs for economic evaluation
6 weeks 6 weeks
the next round
Sustaining for
Drugs listed on the top priority Drugs listed not on the top priority
4 weeks
The health economics working group
Considering those economic evaluation studies and developing policy recommendation
4 weeks
The working group for coordination & consolidation of NLEM
4
The Subcommittee for Development of NLEM
List of drugs under HTA in 2012
6
Classification of interventions as per submissions by stakeholder groups
Stakeholders who submitted health topics
(number of submitted topics)
Total Selected
Interventions classification Policyy Health Healthcare Patient Layy topics
p topics
p for
makers Academics professionals Industry Civic groups associations citizens submitted assessment
Nature of interventions
Medicines* 4 2 - 4 1 1 - 13 5
Devices, equipment and supplies - - - 1 2 - 1 4 2
Medical and surgical procedures 1 - - - - 1 2 7 1
Organizational and managerial systems 1 3 1 1 - 1 3 11 4
Purposes of interventions
Prevention 1 - - - - - - 1 -
Screening and diagnosis †
- 1 1 1 - 1 3 7 3
Treatment 3 3 - 5 2 1 2 16 6
Rehabilitation 1 - - - 1 - - 2 2
C bi ti
Combination 1 1 - - - 1 1 4 1
Target disease of interventions
Non-communicable diseases 4 4 1 5 3 3 5 25 8
Communicable diseases 2 1 - 1 - - - 4 4
Both - - - - - - 1 1 -
Selected topics for assessment 4 3 1 2 1 1 - 12
Recommended Not
Assessment results* Recommended
with restrictions recommended
ICER< 1 per Low
capita budget 2 2 1
GDP/QALY impact
High
budget 1 - 3
impact
ICER >1per Low
capita budget - - -
GDP/QALY impact
High
budget - - 1
impact
* Two cost analysis studies are not included in this table; High budget impact >THB 200 million
per annum; low budget impact ≤200 million per annum